(Q36609208)

15 August 2017

0 references

Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials (English)

1 reference

15 August 2017

1 reference

1 reference

2

Edward V Loftus

1 reference

15 August 2017

3

A Hillary Steinhart

1 reference

15 August 2017

Miguel Regueiro

1

1 reference

15 August 2017

Russell D Cohen

series ordinal

4

1 reference

15 August 2017

publication date

1 October 2006

1 reference

Inflammatory Bowel Diseases

15 August 2017

published in

1 reference

15 August 2017

volume

12

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

979-994

1 reference

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Ulcerative proctitis in central Sweden 1965-1983. A population-based epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Inflammatory bowel disease. Medical therapy of specific clinical presentations

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Intensive intravenous regimen for severe attacks of ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

The role of azathioprine in the management of ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Intravenous azathioprine in severe ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Experience with the use of low-dose methotrexate for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Infliximab for hospitalized patients with severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

A meta-analysis of the role of smoking in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Transdermal nicotine for active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

A randomized trial of nicotine enemas for active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Low molecular weight heparin as adjuvant therapy in active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

The colonic epithelium in ulcerative colitis: an energy-deficiency disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000231495.92013.5E

10.1097/01.MIB.0000231495.92013.5E

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference